Immix Biopharma, Inc.(IMMX) 주가, 분석 및 데이터
내재가치
애널리스트 전망
주가 전망 →$13.20 – $27.00
중앙값 $24.00 · 101.34% 상승 여력
최근 실적
| 발표치 | 예상 대비 | 전년 대비 | |
|---|---|---|---|
| 매출 | $0 | n/a | n/a |
| EPS | -$0.18 | $0.00 | +18.18% |
지표
Immix Biopharma, Inc. 소개
기업 정보 보기 →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.